Business Wire

Velodyne Lidar Introduces Velabit™

Share

Velodyne Lidar, Inc. today introduced Velabit™, Velodyne’s smallest sensor which brings new levels of versatility and affordability to 3D lidar perception, at CES 2020. The Velabit leverages Velodyne’s innovative lidar technology and manufacturing partnerships for cost optimization and high-volume production. The sensor advances Velodyne’s mission to make high-quality 3D lidar sensors readily accessible to everyone.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005849/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Velabit™, Velodyne Lidar’s smallest sensor, brings new levels of versatility and affordability to 3D lidar perception. (Photo: Velodyne Lidar)

The Velabit perfectly complements Velodyne’s sensor portfolio. The sensor delivers the same technology and performance found on Velodyne’s full suite of state-of-the-art sensors and will be the catalyst for creating endless possibilities for new applications in a variety of industries. The compact Velabit can be embedded almost anywhere within vehicles, robots, unmanned aerial vehicles (UAVs), infrastructure and more. It is designed to be easy to manufacture at mass production levels.

The Velabit is engineered to be an optimal automotive grade lidar solution for Advanced Driver Assistance Systems (ADAS) and autonomous vehicles. It enables robust perception coverage for Blind-Spot Monitoring, Cross Traffic Detection, Automatic Emergency Braking, and Pedestrian and Bicyclist Safety. Highly configurable for customer application, this mid-range sensor can be combined with other Velodyne lidar sensors, such as the Velarray™, for high-speed operation or function as a standalone lidar solution in low-speed applications.

The Velabit addresses the cost, safety and design challenges of autonomous solutions while delivering strong sensor performance. Here are the Velabit’s leading features:

  • Integrated processing in a compact size of 2.4” x 2.4” x 1.38” – smaller than a deck of playing cards – to be easily embedded in a wide range of solutions.
  • Range up to 100 meters.
  • Outstanding field of view (FoV): 60-degree horizontal FoV x 10-degree vertical FoV.
  • Highly configurable to support a range of applications.
  • Proven, Class 1 eye-safe 903 nanometer technology.
  • Bottom connector with cable length options.
  • Multiple manufacturing sources scheduled to be available for qualified production projects.

“The Velabit democratizes lidar with its ultra-small form factor and its sensor pricing targeted at $100 in high-volume production, making 3D lidar available for all safety-critical applications,” said Anand Gopalan, Chief Executive Officer, Velodyne Lidar. “Its combination of performance, size and price position the Velabit to drive a quantum leap in the number of lidar-powered applications. The sensor delivers what the industry has been seeking: a breakthrough innovation that can jump-start a new era of autonomous solutions on a global scale.”

“Before the Velabit there was no suitable small and lightweight lidar for small unmanned aerial vehicles and unmanned ground vehicles performing obstacle avoidance or mapping,” said Alberto Lacaze, president, Robotic Research. “Since Robotic Research’s Pegasus Mini™ is a fully autonomous ground and air vehicle, it requires the Velabit’s size and versatility. In addition, the Velabit enables the most advanced GPS-denied HD mapping in the industry. The Velabit fills a much-needed space in the market and is currently in a class of its own.”

The Velabit will be available to customers mid-2020. Velodyne provides world-class technical support for the sensor across North America, Europe and Asia. It is now on display at Velodyne Lidar’s CES 2020 booth located at the Las Vegas Convention Center North Hall – booth #7520.

About Velodyne Lidar

Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s Founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™ and the groundbreaking software for driver assistance, Vella™.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sean Dowdall
Landis Communications Inc. for Velodyne Lidar, Inc.
(415) 286-7121
velodyne@landispr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 23:30:00 EEST | Press release

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 23:05:00 EEST | Press release

IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 22:26:00 EEST | Press release

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 22:24:00 EEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 22:08:00 EEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye